GGrantIndex
← Leaderboards

Yonathan Lissanu

University Of Tx Md Anderson Can Ctr

$6,037,986
Attributed
$6,037,986
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.8M · FY201825
$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,037,986 · 4

By mechanism

R37$3,279,981 · 1
R01$2,112,899 · 1
R21$645,106 · 2

Top collaborators

No co-investigators on record.

Most similar at University Of Tx Md Anderson Can Ctr

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Gene Expression

Research focus

Gene ExpressionFutureIn VivoMortalityTumor GrowthBiologicalBiological ModelsXenograft ProcedureNovel TherapeuticsSmall MoleculeGenesCellsTumorCancer EtiologyMediatingChromatinTargeted TreatmentGene TargetingMutantMutateMalignant Neoplasm Of LungMutationImmunotherapySmarca4 Gene

Grant awards (13)

Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer$952,822
R37 · FY2025 · CA · contact PI
Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancer$537,633
R01 · FY2025 · CA · contact PI
Targeting SMARCA2 to overcome resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors$267,527
R21 · FY2025 · CA · contact PI
Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancer$510,751
R01 · FY2024 · CA · contact PI
Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer$448,439
R37 · FY2024 · CA · contact PI
Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancer$526,882
R01 · FY2023 · CA · contact PI
Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer$462,600
R37 · FY2023 · CA · contact PI
Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancer$537,633
R01 · FY2022 · CA · contact PI
Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer$472,040
R37 · FY2022 · CA · contact PI
Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer$472,040
R37 · FY2021 · CA · contact PI
Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer$472,040
R37 · FY2020 · CA · contact PI
Glucocorticoid Receptor degrading bifunctional molecules as therapeutics in prostate cancer$168,779
R21 · FY2019 · CA · contact PI
Glucocorticoid Receptor degrading bifunctional molecules as therapeutics in prostate cancer$208,800
R21 · FY2018 · CA · contact PI